# NextCure, Inc. (NXTC)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $6M  
**Price:** $2.23

> NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunomedicines for cancer and other immune-related diseases. Headquartered in Beltsville, Maryland, the company concentrates on therapies designed to restore normal immune function rather than broadly suppress or stimulate the immune system. NextCure’s pipeline includes product candidates such as NC410, a fusion protein targeting the LAIR pathway being evaluated in combination with established oncology treatments, and LNCB74, an antibody-drug conjugate directed at the B7-H4 cancer target. The company also advances additional clinical and preclinical programs addressing both oncology and non-oncology indications, including chronic bone diseases and neurodegenerative conditions. Operating within the biotechnology segment of the healthcare sector, NextCure collaborates selectively with partners to progress certain programs, while leveraging its discovery capabilities to identify new immunomodulatory targets. Its activities contribute to the broader immuno-oncology and immune-disease treatment landscape by aiming to provide differentiated, mechanism-based therapeutic options for patients with significant unmet medical needs.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | — | — | -$58M | -$56M | $-19.65 |
| 2024 | — | — | -$57M | -$56M | $-23.88 |
| 2023 | — | — | -$68M | -$63M | $-2.25 |
| 2022 | — | — | -$76M | -$75M | $-2.69 |
| 2021 | — | — | -$71M | -$69M | $-2.51 |
| 2020 | $22M | — | -$41M | -$37M | $-1.33 |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $50M | $15M | $35M | $26M | $4M |
| 2024 | $81M | $15M | $65M | $28M | $5M |
| 2023 | $128M | $14M | $114M | $13M | $6M |
| 2022 | $184M | $17M | $168M | $27M | $7M |
| 2021 | $242M | $9M | $233M | $12M | — |
| 2020 | $307M | $13M | $294M | $33M | $2M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$55M | — | -$50M |
| 2024 | -$44M | -$474,000 | -$41M |
| 2023 | -$53M | -$820,000 | -$54M |
| 2022 | -$58M | -$2M | -$56M |
| 2021 | -$54M | -$2M | -$60M |
| 2020 | -$45M | -$7M | -$52M |

Source: [CompaniesByCap](https://companiesbycap.com/company/NXTC)